Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. We’ve got lots of news this morning, so let’s get straight into it.
Pfizer moves forward a daily GLP-1 obesity pill
Pfizer will advance a once-daily formulation of its oral GLP-1 obesity candidate, danuglipron, after facing multiple setbacks in the space.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect